Biotech and Pharmaceuticals
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. The move comes as the Trump administration ramps up pressure on the pharmaceutical industry to cut drug prices, and threatens to impose sweeping tariffs on pharmaceuticals imported into the […]
Read More
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Boxes of tablets, produced by Novartis AG, sit on a pharmacy counter. Bloomberg | Bloomberg | Getty Images Swiss pharmaceutical firm Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio, as it looks to shift reliance away from its Entresto heart failure therapy. Sales of Kisqali, […]
Read More
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound
Cr | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, […]
Read More
FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says
The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC on Friday. The FDA in June announced a national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are […]
Read More
Trump’s 200% tariff threat leaves pharma firms scrambling with scenario planning
Shelf of pharmaceutical products. D3sign | Moment | Getty Images The pharmaceutical industry is scrambling with scenario planning as U.S. President Donald Trump’s 200% tariff proposal threatens to drive up drug prices and rip out corporate profit margins. The president once again warned on Tuesday that long-awaited industry-wide tariffs would be announced “very soon” after […]
Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January. “Canada is […]
Read More
Merck shells out $10 billion for London-based lung therapy firm Verona
Bloomberg | Bloomberg | Getty Images Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm’s respiratory treatment portfolio in a bid to diversify its revenue source beyond blockbuster cancer drug. Merck has been leaning on its aging cancer immunotherapy Keytruda, the world’s top-selling prescription medicine, […]
Read More
Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’
U.S. President Donald Trump speaks next to Defense Secretary Pete Hegseth during a cabinet meeting at the White House in Washington, D.C., U.S., July 8, 2025. Kevin Lamarque | Reuters President Donald Trump on Tuesday threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. “very soon.” “They’re going to be tariffs […]
Read More
Healthy Returns: Medicaid cuts in Trump’s megabill may affect some drugmakers more than others
U.S. President Donald Trump presents a sweeping spending and tax legislation, known as the “One Big Beautiful Bill Act,” after he signed it, at the White House in Washington, D.C., U.S., July 4, 2025. Leah Millis | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care […]
Read More
Family offices ramp up deal-making in June with bets on biotech
Key Points After a slow spring, investment firms of the ultra-rich made 60 direct investments in June, according to Fintrx. Family offices flocked to biotech and health-care firms such as Antheia, seeking to make an impact and returns at the same time. Antheia founder Christina Smolke told CNBC’s Inside Wealth family offices’ patient capital makes […]
Read More